Filed Pursuant to Rule 424(b)(3)
Registration No. 333-14010
TEVA PHARMACEUTICAL FINANCE N.V.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
SUPPLEMENT NO. 8 DATED JUNE 18, 2003
TO
PROSPECTUS DATED NOVEMBER 14, 2001
AS SUPPLEMENTED
BY
SUPPLEMENT NO. 1 DATED NOVEMBER 28, 2001
AND BY
SUPPLEMENT NO. 2 DATED JANUARY 15, 2002
AND BY
SUPPLEMENT NO. 3 DATED MARCH 22, 2002
AND BY
SUPPLEMENT NO. 4 DATED APRIL 25, 2002
AND BY
SUPPLEMENT NO. 5 DATED SEPTEMBER 11, 2002
AND BY
SUPPLEMENT NO. 6 DATED OCTOBER 9, 2002
AND BY
SUPPLEMENT NO. 7 DATED OCTOBER 23, 2002
This supplement is part of and should be read in conjunction with our
prospectus dated November 14, 2001, as supplemented by Supplement No. 1 dated
November 28, 2001, Supplement No. 2 dated January 15, 2002, Supplement No. 3
dated March 22, 2002, Supplement No. 4 dated April 25, 2002, Supplement No. 5
dated September 11, 2002, Supplement No. 6 dated October 9, 2002, and Supplement
No. 7 dated June 18, 2003 (as supplemented, the "Prospectus"). The information
we present in this supplement supersedes similar information included in the
Prospectus.
We are supplementing the information under the caption "Selling
Securityholders" to revise the number of Debentures and ADRs owned and offered
by an existing Selling Securityholder and to include new Selling Securityholders
and the number of Debentures and ADRs owned and offered thereby:
- --------------------------------------------------------------------------------------------------------------------
Principal
Amount of
Debentures
ADRs Beneficially Owned Owned and ADRs Beneficially Owned
Before Offering (1)(2) Offered ADRs After Offering (2)
Name and Address of Selling ----------------------- Hereby Offered -----------------------
Securityholder Amount Percentage(3) (in $1,000s) Hereby (1) Amount Percentage (3)
- --------------------------- ----- ------------- ------------ ---------- ------ --------------
BTES-Convertible Arb 11,651 * 500 11,651 0 N/A
1585 Avenue of the Americas
New York, New York
- --------------------------------------------------------------------------------------------------------------------
(1) Assumes conversion of all of the selling securityholder's Debentures at a conversion rate of 23.3036 ADRs per
each $1,000 principal amount of debentures (rounded down to the nearest whole ADR) ), which gives effect of the
2-for-1 Teva ordinary share split effected December 10, 2002 (and the related split of ADRs of Teva).
(2) Includes, if applicable, conversion of all the selling securityholder's Teva Pharmaceutical Finance, LLC 1.50%
Convertible Senior Debentures due 2005 at a conversion rate of 23.1934 ADRs per each $1,000 principal amount of
debentures (rounded down to the nearest whole ADR) ), which gives effect of the 2-for-1 Teva ordinary share split
effected December 10, 2002 (and the related split of ADRs of Teva). Also includes, if applicable, conversion of all
the selling security holder's Teva Pharmaceutical Finance B.V. 0.375% Convertible Sensor Debentures due 2022 at a
conversion rate of 23.3106 ADRs per each $1,000 principal amount of debentures (rounded down to the nearest whole
ADR), which gives effect of the 2-for-1 Teva ordinary share split effected December 10, 2002 (and the related split
of ADRs of Teva).
(3) Except as noted, assumes that Debentures held by other holders are not converted.
* Less than 1%
- --------------------------------------------------------------------------------------------------------------------
Principal
Amount of
Debentures
ADRs Beneficially Owned Owned and ADRs Beneficially Owned
Before Offering (1)(2) Offered ADRs After Offering (2)
Name and Address of Selling ----------------------- Hereby Offered -----------------------
Securityholder Amount Percentage(3) (in $1,000s) Hereby (1) Amount Percentage (3)
- --------------------------- ----- ------------- ------------ ---------- ------ --------------
BTOP-Growth Vs Value 46,607 * 2,000 46,607 0 N/A
1585 Avenue of the Americas
New York, New York
JP Morgan Securities Inc. 125,968 * 5,000 116,518 9,450 *
500 Stanton Christiana Road
Newark, Delaware 19713
- --------------------------------------------------------------------------------------------------------------------
(1) Assumes conversion of all of the selling securityholder's Debentures at a conversion rate of 23.3036 ADRs per
each $1,000 principal amount of debentures (rounded down to the nearest whole ADR) ), which gives effect of the
2-for-1 Teva ordinary share split effected December 10, 2002 (and the related split of ADRs of Teva).
(2) Includes, if applicable, conversion of all the selling securityholder's Teva Pharmaceutical Finance, LLC 1.50%
Convertible Senior Debentures due 2005 at a conversion rate of 23.1934 ADRs per each $1,000 principal amount of
debentures (rounded down to the nearest whole ADR) ), which gives effect of the 2-for-1 Teva ordinary share split
effected December 10, 2002 (and the related split of ADRs of Teva). Also includes, if applicable, conversion of all
the selling security holder's Teva Pharmaceutical Finance B.V. 0.375% Convertible Sensor Debentures due 2022 at a
conversion rate of 23.3106 ADRs per each $1,000 principal amount of debentures (rounded down to the nearest whole
ADR), which gives effect of the 2-for-1 Teva ordinary share split effected December 10, 2002 (and the related split
of ADRs of Teva).
(3) Except as noted, assumes that Debentures held by other holders are not converted.
* Less than 1%